Headlines about NxStage Medical (NASDAQ:NXTM) have trended somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NxStage Medical earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news headlines about the medical device company an impact score of 45.8275264319887 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern’s analysis:
- NxStage Medical, Inc. (NXTM) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- NxStage Medical : Announces Winners of Third Annual Nurse Hero Award (4-traders.com)
- NxStage Announces Winners of Third Annual Nurse Hero Award (finance.yahoo.com)
- NxStage Medical, Inc. (NXTM) Rating Reiterated by Canaccord Genuity (americanbankingnews.com)
A number of equities analysts recently issued reports on NXTM shares. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Thursday, August 10th. Craig Hallum started coverage on NxStage Medical in a report on Tuesday, June 27th. They issued a “buy” rating and a $32.00 price target for the company. BTIG Research downgraded NxStage Medical from a “buy” rating to a “neutral” rating in a report on Friday, August 11th. Canaccord Genuity downgraded NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target for the company. in a report on Monday, August 7th. Finally, BidaskClub downgraded NxStage Medical from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating and eight have issued a hold rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $30.25.
Shares of NxStage Medical (NASDAQ:NXTM) traded down 0.18% during trading on Monday, reaching $27.46. The company had a trading volume of 250,259 shares. The company’s market capitalization is $1.81 billion. The firm has a 50-day moving average price of $27.66 and a 200-day moving average price of $25.91. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80.
NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The company had revenue of $92.20 million for the quarter, compared to the consensus estimate of $96.47 million. During the same period in the previous year, the business earned ($0.03) EPS. NxStage Medical’s revenue for the quarter was up .0% compared to the same quarter last year. On average, analysts predict that NxStage Medical will post ($0.05) EPS for the current fiscal year.
In other news, President Joseph E. Turk, Jr. sold 24,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $29.64, for a total value of $711,360.00. Following the completion of the sale, the president now directly owns 82,903 shares in the company, valued at approximately $2,457,244.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Joseph E. Turk, Jr. sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $22.98, for a total value of $160,860.00. Following the completion of the sale, the president now owns 82,903 shares of the company’s stock, valued at $1,905,110.94. The disclosure for this sale can be found here. Insiders sold a total of 46,100 shares of company stock valued at $1,302,132 over the last quarter. Company insiders own 4.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/10/23/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-nxstage-medical-nxtm-stock-price.html.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.